抗蛋白精氨酸甲基转移酶5(PRMT5)抗体的鉴定与验证:系统性硬化症(SSc)的新型生物标志物
研究采用免疫沉淀联合质谱的全局抗体谱策略,在系统性硬化症患者中鉴定出抗PRMT5抗体显著升高,其区分SSc与健康对照及其他自身免疫病的曲线下面积为0.900至0.988;31.11%的SSc患者该抗体血清阳性,且抗体滴度与SSc进展或缓解轨迹相关;小鼠免疫PRMT5后皮肤和肺出现显著炎症与纤维化。
要点
- 抗PRMT5抗体在SSc患者中显著升高,区分SSc与健康对照及SLE、干燥综合征的AUC为0.900至0.988。
- 31.11%的SSc患者抗PRMT5抗体血清阳性,滴度与SSc进展或缓解轨迹相关。
- 小鼠免疫PRMT5后皮肤和肺出现显著炎症与纤维化,伴多条促炎和促纤维化通路上调。
核心结论
- 本研究鉴定出抗PRMT5抗体可作为系统性硬化症的新型生物标志物。
研究设计与样本
- 采用免疫沉淀联合磁珠酶解及基于质谱的定量蛋白质组学策略,对SSc患者或健康供者血清进行全局抗体谱分析。
- 候选抗体在两个独立的SSc患者组中正交验证,其中一组采用微阵列法。
- 用目标抗原免疫小鼠,随后进行组织学检查和RNA测序评估。
主要发现
- 免疫沉淀-质谱分析及在SSc患者中的验证显示,SSc患者抗PRMT5抗体显著升高。
- 抗PRMT5抗体区分SSc与健康对照及其他自身免疫病(包括系统性红斑狼疮和干燥综合征)的曲线下面积为0.900至0.988。
- 在随后采用微阵列法的独立SSc组中验证了抗PRMT5抗体升高。
- 31.11%的SSc患者抗PRMT5抗体血清阳性。
- 抗PRMT5抗体滴度与SSc的进展或缓解轨迹相关。
关键数值与推荐
- 抗PRMT5抗体区分SSc与健康对照及其他自身免疫病的曲线下面积为0.900至0.988。
- 31.11%的SSc患者抗PRMT5抗体血清阳性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In the complex panorama of autoimmune diseases, the characterisation of pivotal contributing autoantibodies that are involved in disease progression remains challenging. This study aimed to employ a global antibody profiling strategy to identify novel antibodies and investigate their association with systemic sclerosis (SSc). METHODS: We implemented this strategy by conducting immunoprecipitation (IP) following on-bead digestion with the sera of patients with SSc or healthy donors, using antigen pools derived from cell lysates. The enriched antigen-antibody complex was proceeded with mass spectrometry (MS)-based quantitative proteomics and over-represented by bioinformatics analysis. The candidate antibodies were then orthogonally validated in two independent groups of patients with SSc. Mice were immunised with the target antigen, which was subsequently evaluated by histological examination and RNA sequencing. RESULTS: The IP-MS analysis, followed by validation in patients with SSc, revealed a significant elevation in anti-PRMT5 antibodies among patients with SSc. These antibodies exhibited robust diagnostic accuracy in distinguishing SSc from healthy controls and other autoimmune conditions, including systemic lupus erythematosus and Sjögren's syndrome, with an area under the curve ranging from 0.900 to 0.988. The elevation of anti-PRMT5 antibodies was verified in a subsequent independent group with SSc using an additional method, microarray. Notably, 31.11% of patients with SSc exhibited seropositivity for anti-PRMT5 antibodies. Furthermore, the titres of anti-PRMT5 antibodies demonstrated a correlation with the progression or regression trajectory in SSc. PRMT5 immunisation displayed significant inflammation and fibrosis in both the skin and lungs of mice. This was concomitant with the upregulation of multiple proinflammatory and profibrotic pathways, thereby underscoring a potentially pivotal role of anti-PRMT5 antibodies in SSc. CONCLUSIONS: This study has identified anti-PRMT5 antibodies as a novel biomarker for SSc.
引用
- Liang M, Wang L, Tian X, et al. Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc). Ann Rheum Dis. 2024. PMID: 38684324. doi:10.1136/ard-2024-225596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。